Investor directory

Vitalife

Vitalife Partners is a private equity and venture capital firm established in 2002 and headquartered in Malvern, Pennsylvania, with additional offices in Wayne, Pennsylvania, and Tel-Aviv, Israel. The firm focuses on early and mid-stage investments in life science companies, particularly in sectors such as therapeutic medical devices, novel diagnostics, biomaterials, specialty pharmaceuticals, drug delivery, and healthcare services. Vitalife Partners typically invests between $0.5 million and $7 million in individual companies, aiming for total investments ranging from $7 million to $15 million throughout the investment period. The firm is committed to providing hands-on strategic assistance, leveraging its extensive networks and the expertise of its team, which includes experienced professionals from various sectors within the life sciences.

Focus

PharmaceuticalsLife and Health InsuranceLife ScienceWellnessScale StageShow more
http://www.scpvitalife.com
https://crunchbase.com/organization/scp-vitalife-partners
https://linkedin.com/company/scp-vitalife
https://pitchbook.com/profiles/investor/11330-11
https://www.capitaliq.com/CIQDotNet/company.aspx?companyId=59197061
https://www.privateequityinternational.com/database/#/profile?id=9061

Winston Churchill

Managing General Partner

Jeff Dykan

Managing Partner

Dennis P. Ferry

CFO

Geraldine A. Henwood

Venture Partner

Edna Ludomirski

Venture Partner

Abraham Ludomirski

Partner

Adi Shaked

Associate

Wayne B. Weisman

Partner

17 past transactions

Sensible Medical Innovations

Venture Round in 2013
Sensible Medical Innovation Ltd develops medical radar monitoring and imaging technology solutions. The company offers ReDS, a solution for monitoring and management of lung fluid in patients with heart failure and other fluid management problems. Sensible Medical Innovation Ltd was founded in 2007 and is based in Netanya, Israel.

Avedro

Series D in 2013
Medical device and pharmaceutical company advancing the science and technology of corneal cross-linking

MST Medical Surgery Technologies

Series C in 2015
MST Medical Surgery Technologies Ltd. develops image analysis software for healthcare industry. It develops an image analysis software AutoLap, that facilitates robotic surgery, provides control of surgical procedure and an optimal field of view to surgeons; and Surgical Training Analytics (STA), a tool to captures images from actual surgical procedures performed by the surgeon in training. The company was founded in 2005 and is based in Tel Aviv, Israel with additional office in Apollo Beach, Florida.

NovoGI

Series F in 2009
novoGI™ (previously NiTi Surgical Solutions) is committed to advancing patient care by providing an expanding range of comprehensive solutions for GI disease management. NiTi Surgical Solutions has developed the first major advance in closure for gastrointestinal surgery in more than 30 years. NiTi's proprietary technology represents a breakthrough in natural healing with tissue-sparing, uniform BioDynamix anastomosis. The company's unique line of products utilizes Nitinol-based elements to press together the ends of resected tissue, enabling a natural reconnection of the intestine after removing a section, for example, as part of a colon cancer treatment. The company is commercializing a family of FDA-cleared and CE-marked disposable tissue closure devices.

Avedro

Venture Round in 2012
Medical device and pharmaceutical company advancing the science and technology of corneal cross-linking

Regentis Biomaterials

Series D in 2016
Regentis Biomaterials is a privately held company focused on developing and commercializing proprietary hydrogels for tissue regeneration. The company’s core technology is a iodegradable hydrogel called Gelrin™. It is based on polyethylene glycol diacrylate and denatured fibrinogen originally developed at the Technion University by Dr. Dror Seliktar. The Gelrin hydrogel platform combines the stability and versatility of a synthetic material with the bio-functionality of a natural substance for a range of clinical applications and has undergone extensive preclinical and safety testing over the last few years. The company’s flagship product, GelrinC™,designed for the treatment of articular cartilage lesions, is currently in clinical trials.

Ivenix

Venture Round in 2015
Ivenix is a medical technology company that develops a next-generation infusion management system. It is a venture-backed medical device company with a vision to transform infusion delivery in every care setting, globally. The company is focused on bringing its first product to market, a new and innovative infusion management system for hospitals. The system combines integrated state-of-the-art information technology and simplicity with an adaptive fluid delivery platform that continuously measures flow. The company was founded in 2007 and is headquartered in Amesbury, Massachusetts.

MST Medical Surgery Technologies

Series C in 2015
MST Medical Surgery Technologies Ltd. develops image analysis software for healthcare industry. It develops an image analysis software AutoLap, that facilitates robotic surgery, provides control of surgical procedure and an optimal field of view to surgeons; and Surgical Training Analytics (STA), a tool to captures images from actual surgical procedures performed by the surgeon in training. The company was founded in 2005 and is based in Tel Aviv, Israel with additional office in Apollo Beach, Florida.

Fluidnet

Series C in 2011
Fluidnet was founded in 2002 by a group of medical device professionals who collectively have over 100+ years of industry experience and product innovations. Based on the seacoast of scenic New Hampshire, Fluidnet is just north of Boston, providing access to a rich medical device community and first-rate research and development skills and facilities.

Rewalk Robotics

Series D in 2013
ReWalk Robotics Ltd., a medical device company, designs, develops, and commercializes robotic exoskeletons for individuals with mobility impairments or other medical conditions. It offers ReWalk Personal for everyday use to paraplegic individuals at home and in their communities; and ReWalk Rehabilitation for exercise and therapy used in hospitals and rehabilitation centers in the United States and Europe. The company is also developing ReWalk Restore, a soft suit exoskeleton for rehabilitation of individuals suffering from a stroke. It markets and sells its products directly to third party payers, institutions and individuals, as well as through third-party distributors. The company was formerly known as Argo Medical Technologies Ltd. ReWalk Robotics Ltd. was founded in 2001 and is headquartered in Yokneam Ilit, Israel.

Regentis Biomaterials

Series C in 2012
Regentis Biomaterials is a privately held company focused on developing and commercializing proprietary hydrogels for tissue regeneration. The company’s core technology is a iodegradable hydrogel called Gelrin™. It is based on polyethylene glycol diacrylate and denatured fibrinogen originally developed at the Technion University by Dr. Dror Seliktar. The Gelrin hydrogel platform combines the stability and versatility of a synthetic material with the bio-functionality of a natural substance for a range of clinical applications and has undergone extensive preclinical and safety testing over the last few years. The company’s flagship product, GelrinC™,designed for the treatment of articular cartilage lesions, is currently in clinical trials.

CanFite BioPharma

Venture Round in 2002
Can-Fite BioPharma (TASE:CFBI; NYSE MKT:CANF) is an Israeli biopharmaceutical company with fully integrated pharmaceutical discovery and clinical development capabilities. The company has an advanced pipeline of proprietary compounds in phase 2 and 3 clinical development stage, which address autoimmune-inflammatory and cancer diseases.

Sightline Technologies

Series D in 2005
Sightline Technologies Ltd. provides medical products and services. The Company designs, develops, and markets a colonoscope with a disposable tube and sheath, which is used for diagnosing and treating abnormalities in the large intestine. Sightline Technologies primarily operates in Israel.

Garnet Biotherapeutics

Series A in 2009
Garnet BioTherapeutics is a clinical stage, venture-backed cell therapy company focused on dermal-based regenerative therapy.

Beta-O2 Technologies

Venture Round in 2004
Beta-O2 Technologies Ltd., a biomedical company, develops implantable bioreactors. It offers ßAir Bio-artificial Pancreas for the treatment and potential cure for type 1 diabetes (T1D). The company also engages in the development of ßAir Bio-artificial Adrenal for the treatment of adrenocortical insufficiency and other stress-related disorders. Beta-O2 Technologies Ltd. was founded in 2004 and is based in Rosh HaAyin, Israel.

GeneGrafts

Seed Round in 2003
GeneGrafts Ltd. develops therapeutic products to treat cardiac arrhythmia, Parkinson's disease, and epilepsy. The company is also known as GreenGrafts Ltd. It was founded in November 2003 and is based in Haifa, Israel.

Avedro

Series C in 2011
Medical device and pharmaceutical company advancing the science and technology of corneal cross-linking